Molecular biology of inflammation and sepsis: A primer*

Critical Care Medicine

Volumn 37, Issue 1, 2009, Pages 291-304

  Cinel, Ismail ^a   Opal, Steven M ^b  

^a University of Medicine   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Activated protein C; Apoptosis; neutrophils; mitochondrial dysfunction; Inflammasome; Inflammation; Nitric oxide; Peroxynitrite; Reactive oxygen species; Sepsis; Signalosome; Toll like receptors

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; ACTIVATED PROTEIN C; ATORVASTATIN; AZD 9773; CITRULLINE; DROTRECOGIN; ERITORAN; ERYTHROPOIETIN; GR 270773; HIGH MOBILITY GROUP B1 PROTEIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PATTERN RECOGNITION RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROLYLLEUCYLGLYCINAMIDE; RECOMBINANT ANTITHROMBIN III; RECOMBINANT HUMAN LACTOFERRIN; RECOMBINANT PLASMA GELSOLIN; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RETINOIC ACID INDUCIBLE PROTEIN I; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; SIMVASTATIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; CYTOKINE;

APOPTOSIS; BLOOD CLOTTING; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MEDICAL RESEARCH; MEDLINE; MOLECULAR BIOLOGY; MONOCYTE; NEUTROPHIL; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICIAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; SEPTIC SHOCK; SEVERE SEPSIS; SIGNAL TRANSDUCTION; ANIMAL; IMMUNOLOGY; MITOCHONDRION; PHYSIOLOGY;

ANIMALS; BLOOD COAGULATION; CYTOKINES; HUMANS; INFLAMMATION; MACROPHAGES; MITOCHONDRIA; MOLECULAR BIOLOGY; MONOCYTES; NEUTROPHILS; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 59649117667     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819267fb     Document Type: Review

References (190)

1. van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43
2. Cinel I, Dellinger RP: Making a difference in outcome in severe sepsis: The organism, the host response and the treating clinician. Emerg Med Crit Care Rev 2007; 1:1-3
3. Cinel I, Dellinger RP: Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007; 20:345-352
4. Uematsu S, Akira S: Toll-like receptors and innate immunity. J Mol Med 2007; 84: 712-725
5. Creagh EM, O'Neill LA: TLRs, NLRs and RLRs: A trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27:352-357
6. Granucci F, Foti M, Ricciardi-Castagnoli P: Dendritic cell biology. Adv Immunol 2005; 88:193-233
7. Liew FY, Xu D, Brint EK, et al: Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-458
8. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124:783-801
9. Bianchi ME: DAMPs PAM. Ps and alarmins: All we need to know about danger. J Leukoc Biol 2007; 81:1-5
10. Mollen KP, Anand RJ, Tsung A, et al: Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26:430-437
11. Tsujimoto H, Ono S, Hiraki S, et al: Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock. J Endotoxin Res 2004; 10:229-237
12. Armstrong L, Medford AR, Hunter KJ, et al: Differential expression of toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 2004; 136: 312-319
13. Tsujimoto H, Ono S, Majima T, et al: Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 2005; 23:39-44
14. Williams DL, Ha T, Li C, et al: Modulation of tissue toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 2003; 31:1808-1818
15. Paterson HM, Murphy TJ, Purcell EJ, et al: Injury primes the innate immune system for enhanced toll-like receptor reactivity. J Immunol 2003; 171:1473-1483
16. Tsujimoto H, Ono S, Efron PA, et al: Role of toll like receptors in the development of sepsis. Shock 2008; 29:315-321
17. Ogura Y, Sutterwala FS, Flavell RA: The inflammasome: First line of the immune response to cell stress. Cell 2006; 126: 659-662
18. Drenth JP, van der Meer JW: The inflammasome - A linebacker of innate defense. N Engl J Med 2006; 355:730-732
19. Dinarello CA: Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme. Ann NY Acad Sci 1998; 856:1-11
20. Martinon F, Burns K, Tschopp J: The inflammasome. A molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. MolCell 2002; 10: 417-426
21. Yu JW, Wu J, Zhang Z, et al: Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 2005; 13:236-249
22. Seshadri S, Duncan MD, Hart JM, et al: Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1β processing and release. J Immunol 2007; 179:1274-1281
23. Tschopp J, Martinon F, Burns K: NALPs: A novel protein family involved in inflammation. NatRevMol Cell Biol 2003; 4:95-104
24. Sarkar A, Duncan M, Hart J, et al: ASC directs NF-kB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. J Immunol 2006; 176:4979-4986
25. Scott AM, Saleh M: The inflammatory caspases: Guardians against infections and sepsis. Cell Death Differ 2007; 14:23-31
26. Sarkar A, Hall MW, Exline M, et al: Caspase-1 regulates E. coli sepsis and splenic B cell apoptosis independently of IL-1β and IL-18. Am J Respir Crit Care Med 2006; 174:1003-1010
27. Saleh M, Vaillancourt JP, Graham RK, et al: Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429:75-79
28. Saleh M, Mathison JC, Wolinski MK, et al: Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 2006; 440:1064-1068
29. Joshi VD, Kalvakolanu DV, Hasday JD, et al: IL-18 levels and the outcome of innate immune response to lipopolysaccharide: Importance of a positive feedback loop with caspase-1 in IL-18 expression. J Immunol 2002; 169:2536-2544
30. Fahy RJ, Exline MC, Gavrilin MA, et al: Inflammasome mRNA expression in human monocytes during early septic shock. Am J Resp Crit Care Med 2008; 177:983-988.
31. Lara-Tejero M, Sutterwala FS, Ogura Y, et al: Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med 2006; 203:1407-1412
32. Brightbill HD, Libraty DH, Krutzik SR, et al: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999; 285:732-736
33. Bruno TF, Woods DE, Mody CH: Exoenzyme S from Pseudomonas aeruginosa induces apoptosis in T lymphocytes. J Leukoc Biol 2000; 67:808-816
34. Wesche H, Henzel WJ, Shillinglaw W, et al: MyD88: An adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997; 7:837-847
35. Reynaert NL, van der Vliet A, Guala AS, et al: Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci USA 2006; 103: 13086-13091
36. Pahl HL: Activators and target genes of rel/ NF-kappaB transcription factors. Oncogene 1999; 18:6853-6866
37. Blackwell TS, Yull FE, Chen CL, et al: Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation. Am J Respir Crit Care Med 2000; 162:1095-1101
38. Arcaroli J, Silva E, Maloney JP, et al: Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006; 173:1335-1341
39. Zaph C, Troy AE, Taylor BC, et al: Epithelial cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007; 446:552-556
40. Liu YJ, Soumelis V, Watanabe N, et al: TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 2007; 25:193-219
41. Peck-Palmer OM, Unsinger J, Chang KC, et al: Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol 2008; 83:1009-1018
42. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-1657
43. Okugawa S, Ota Y, Kitazawa T, et al: Janus kinase2 is involved in lipopolysaccharide-induced activation of macrophages. Am J Physiol Cell Physiol 2003; 285:C399-C408
44. Ojaniemi M, Glumoff V, Harju K, et al: Phosphatidylinositol kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 2003; 335:97-605
45. Guillot L, Le GofficR, BlochS, et al: Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005; 280:5571-5580
46. Wrann CD, Tabriz NA, Barkhausen T, et al: The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions. J Immunol 2007; 178:5940-5948
47. Guha M, Mackman N: The PI3K-Akt pathway limits LPS activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277:32124-32132
48. Schabbaue G, Tencati M, Pedersen B, et al: PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 2004; 24: 1963-1969
49. Pengal RA, Ganesan LP, Wei G, et al: Lipopolysaccharide-induced production of interleukin-10 is promoted by the serin threonine kinase Akt. Mol Immunol 2006; 43: 1557-1156
50. Fukao T, Koyasu S: PI3K and negative regulation of TLR signaling. Trends Immunol 2003; 24:358-363
51. Bommhardt U, Chang KC, Swanson PE, et al: Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2004; 172:7583-7591
52. Mc Dunn JE, Muenzer JT, Rachdi L, et al: Peptide-mediated activation of Akt and extracellular regulated kinase signaling prevents lymphocyte apoptosis. FASEB J 2008; 22:561-568
53. Hall A: Rho GT. Pases and the actin cytoskeleton. Science 1998; 279:509-514
54. Ruse M, Knaus UG: New players in TLR-mediated innate immunity. Immunologic Res 2006; 34:33-48
55. Arbibe L, Mira JP, Teusch N, et al: Toll-like receptor 2-mediated NF-kappa B activation requires a Racl dependenpt pathway. Nat Immunol 2000; 1:533-540
56. Honing H, van den Berg TK, van der Pol SM, et al: Rho activation promotes transendothelial migration of monocytes via ROCK. J Leukoc Biol 2004; 75:523-528
57. Tasaka S, Koh H, Yamada W, et al: Attenuation of endotoxin-induced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. Am J Respir Cell Mol Biol 2005; 32:504-510
58. Thorlacius K, Slotta JE, Laschke MW, et al: Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury. J Leukoc Biol 2006; 79:923-931
59. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor FoxP3. Science 2003; 299: 1057-1061
60. Zheng SG, Wang JH, Koss MN, et al: CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory Graft-versus- Host disease with a Lupus-like syndrome. J Immunol 2004; 172:1531-1539
61. Ausubel FM: Are innate immune signaling pathways in plants and animals conserved? Nat Immunol 2005; 6:973-979
62. Caramalho I, Lopes-Carvalho T, Ostler D, et al: Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403-411
63. Sutmuller RPM, den Brok MH, Kramer M, et al: Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006; 116:485-494
64. Liu H, Komai-Koma M, Xu D, et al: Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006; 103: 7048-7053
65. McHugh RS, Shevach EM: The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002; 110:693-702
66. + regulatory T cells control innate immune reactivity after injury. J Immunol 2005; 174:2957-2963
67. Monneret G, Debard AL, Venet F, et al: Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003; 31:2068-2071
68. Venet F, Pachot A, Debard AL, et al: Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25-lymphocytes. Crit Care Med 2004; 32:2329-2331
69. Takahashi H, Tsuda Y, Takeuchi D, et al: Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med 2004; 32:1879-1885
70. Tiemessen MM, Jagger AL, Evans HG, et al: CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007; 104:19446-19451
71. Wisnoski N, Chung CS, Chen Y, et al: The contribution of CD4+ CD25+ T-regulatory-cells to immune suppression in sepsis. Shock 2007; 27:251-257
72. van Maren WW, Jacobs JF, de Vries IJ, et al: Toll-like receptor signalling on Tregs: To suppress or not to suppress? Immunology 2008; 124:445-452.
73. + regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J Immunol 2005; 174:7141-7146
74. Venet F, Pachot A, Debard AL, et al: Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol 2006; 177: 6540-6547
75. Brown KA, Brain SD, Pearson JD, et al: Neutrophils in development of multiple organ failure in sepsis. Lancet 2006; 368: 157-169
76. Marshal JC: The pathogenesis and molecular biology of sepsis. Crit Care Resusc 2006; 8:227-229
77. Chandra A, Enkhbaatar P, Nakano Y, et al: Sepsis: Emerging role of nitric oxide and selectins. Clinics 2006; 61:71-76
78. Hu G, Predescu D, Vogel SM: ICAM-1 dependent neutrophil adhesion to endothelial cells increases caveolae-mediated pulmonary vascular albumin permeability. Crit Care Med 2007; 34 (Suppl 12): A31
79. Garrean S, Gao X-P, Brovkovych V, et al: Caveolin-1 regulates NF-kB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol 2006 177: 4853-4860
80. Wang XM, Kim HP, Song R, et al: Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol 2006; 34:434-442
81. Medina FA, de Almeida CJ, Dew E, et al: Caveolin-1 deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar typhimurium infection. Infect Immun 2006; 74:6665-6674
82. Medina FA, Cohen AW, de Almeida CJ, et al: Immune dysfunction in caveolin-1 null mice following infection with Trypanosoma cruzi (Tulahuen strain). Microbes Infect 2007; 9:325-333
83. Astiz ME, DeGent GE, Lin RY, et al: Microvascular function and rheologic changes in hyperdynamic sepsis. Crit Care Med 1995; 23:265-271
84. Ozdulger A, Cinel I, Koksel O, et al: The protective effect of N-acetylcysteine on apoptotic lung injury in cecal ligation and puncture-induced sepsis model. Shock 2003; 19:366-372
85. Stehr SN, Knels L, Weissflog C, et al: Effects of IgM enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia. Shock 2007; 29:167-172
86. Kabay B, Kocaefe C, Baykal A, et al: Interleukin-10 gene transfer: Prevention of multiple organ injury in a murine cecal ligation and puncture model of sepsis. World J Surg 2007; 31:105-115
87. Ozdulger A, Cinel I, Unlu A, et al: Poly (ADP-ribose) synthetase inhibition prevents lipopolysaccharide-induced peroxynitrite mediated damage in diaphragm. Pharmacol Res 2002; 46:67-73
88. Taner S, Cinel I, Ozer L, et al: Poly (ADP-ribose) synthetase inhibition reduces bacterial translocation in rats after endotoxin challenge. Shock 2001; 16:159-162
89. Cinel I, Buyukafsar K, Cinel L, et al: The role of poly (ADP-ribose) synthetase inhibition in preventing endotoxemia-induced intestinal epithelial apoptosis. Pharmacol Res 2002; 46:119-127
90. Savill J: Apoptosis in resolution of inflammation. J Leukoc Biol 1997; 61:375-380
91. Maianski NA, Geissler J, Srinivasula SM, et al: Functional characterization of mitochondria in neutrophils: A role restricted to apoptosis. Cell Death Differ 2004; 11: 143-153
92. van Raam BJ, Verhoeven AJ, Kuijpers TW: Mitochondria in neutrophil apoptosis. Int J Hematol 2006; 84:199-204
93. Sookhai S, Wang JJ, McCourt M, et al: A novel therapeutic strategy for attenuating neutrophil-mediated lung injury in vivo. Ann Surg 2002; 235:285-291
94. Taneja R, Parodo J, Kapus A, et al: Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity. Crit Care Med 2004; 32:1460-1469
95. Fadok VA, Bratton DL, Konowal A, et al: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF, PGE2, and PAF. J Clin Invest 1998; 101:890-898
96. Sanford AN, Suriano AR, Herche D, et al: Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology 2006; 45:178-181
97. Daleke DL: Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003; 44:233-242
98. Bayir H, Kagan VE: Bench-to-bedside review: Mitochondrial injury, oxidative stress and apoptosis - there is nothing more practical than a good theory. Crit Care 2008; 12:206
99. Tyurina YY, Basova LV, Konduru NV, et al: Nitrosative stress inhibits the aminophospholipid translocase resulting in phosphati-dylserine externalization and macrophage engulfment: Implications for the resolution of inflammation. J Biol Chem 2007; 282: 8498-8509
100. Swan R, Chung CS, Albina J, et al: Polymicrobial sepsis enhances clearance of apoptotic immune cells by splenic macrophages. Surgery 2007; 142:253-261
101. Macdonald J, Galley HF, Webster NR: Oxidative stress and gene expression in sepsis. Br J Anaest 2003; 90:221-232
102. Matejovic M, Krouzecky A, Rokyta R Jr, et al: Effects of combining inducible nitric oxide synthase inhibitor and radical scavenger during porcine bacteremia. Shock 2007; 27: 61-68
103. Fialkow L, Wang Y, Downey GP: Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007; 42:153-164
104. Galley HF, Davies MJ, Webster NR: Xanthine oxidase activity and free radical generation in patients with sepsis syndrome. Crit Care Med 1996; 24:1649-1653
105. Soriano FG, Nogueira AC, Caldini EG, et al: Potential role of poly (adenosine 5′-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 2006; 34: 1073-1079
106. Ulloa L, Tracey KJ: The "cytokine profile": A code for sepsis. Trends Mol Med 2005; 11: 56-63
107. Zimmermann K, Volkel D, Pable S, et al: Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation 2004; 28:221-229
108. Rouhiainen A, Tumova S, Valmu L, et al: Pivotal advance: Analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukocyte Biol 2007; 81:49-58
109. Bonaldi T, Talamo F, Scaffidi P, et al: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22:5551-5560
110. Youn JH, Shin JS: Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 2006; 177:7889-7897
111. Bell CW, Jiang W, Reich CF III, et al: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291:C1318-C1325
112. Qin S, Wang H, Yuan R, et al: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203:1637-1642
113. Hori O, Brett J, Slattery T, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin: Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270:25752-25761
114. Park JS, Svetkauskaite D, He Q, et al: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7377
115. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251
116. Mitola S, Belleri M, Urbinati C, et al: Cutting edge: Extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176:12-15
117. Tzeng HP, Fan J, Vallejo JG, et al: Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. Am J Physiol Heart Circ Physiol 2008; 294:H1490-H1496
118. Wang H, Yu M, Ochani M, et al: Nicotinic acetylcholine receptor α7 receptor is an essential regulator of inflammation. Nature 2003; 421:384-388
119. Pavlov VA, Wang H, Czura CJ, et al: The cholinergic anti-inflammatory pathway: A missing link in neuromodulation. Mol Med 2003; 9:125-134
120. Wang H, Liao H, Ochani M, et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10:1216-1221
121. Huston JM, Gallowitsch-Puerta M, Ochani M, et al: Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 2007; 35: 2762-2768
122. Goldstein RS, Bruchfeld A, Yang L, et al: Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007; 13(3-4):210-215
123. Youn JH, Oh YJ, Kim ES, et al: High Mobility Group Box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-{alpha} production in human monocytes. J Immunol 2008; 180:5067-5074
124. Sha Y, Zmijewski J, Xu Z, et al: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008; 180:2531-2537
125. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33: 564-573
126. Gibot S, Massin F, Cravoisy A, et al: High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007; 33:1347-1353
127. Karlsson S, Pettilä V, Tenhunen J, et al: HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 2008; 34:1046-1053.
128. Harris HE, Raucci A: Alarmin(g) news about danger. EMBO Rep 2006; 7:774-778
129. Chavakis T, Bierhaus A, Al-Fakhri N, et al: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198:1507-1515
130. Lutterloh EC, Opal SM, Pittman DD, et al: Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:R122
131. Calandra T, Bernhagen J, Metz CN, et al: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377: 68-71
132. Calandra T, Echtenacher B, Roy DL, et al: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-170
133. Bozza M, Satoskar AR, Lin G, et al: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189:341-346
134. Roger T, David J, Glauser MP, et al: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414:920-924
135. Mitchell RA, Liao H, Chesney J, et al: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002; 99:345-350
136. Kreymann G, Grosser S, Buggisch P, et al: Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock. Crit Care Med 1993; 21:1012-1019
137. Rosser DM, Stidwill RP, Jacobson D, et al: Oxygen tension in the bladder epithelium rises in both high and low cardiac output endotoxemic sepsis. J Appl Physiol 1995; 79:1878-1882
138. Hotchkiss RS, Swanson PE, Freeman BD, et al: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-1251
139. Brealey D, et al: Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004; 286:R491-R497
140. Crouser ED: Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004; 4:729-741
141. Fink MP: Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clinics 2001; 17:219-237
142. Brealey D, Brand M, Hargreaves I, et al: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360:219-223
143. Crouser ED, Julian MW, Blaho DV, et al: Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit Care Med 2002; 30:276-284
144. Levy PJ, Vijayasarathy C, Raj NR, et al: Competitive and noncompetitive inhibition of myocardial cytochrome C oxidase in sepsis. Shock 2004; 21:110-114
145. Rabuel C, Renaud E, Brealey D, et al: Human septic myopathy: Induction of cyclooxygenase, heme oxygenase and activation of the ubiquitin proteolytic pathway. Anesthesiology 2004; 101:583-590
146. Larche J, Lancel S, Hassoun SM, et al: Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. J Am Coll Cardiol 2006; 48:377-385
147. Levi M, Ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592
148. Schouten M, Wiersinga WJ, Levi M, et al: Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536-545
149. Opal SM: The nexus between systemic inflammation and disordered coagulation in sepsis. J Endotoxin Res 2004; 10:125-129
150. Esmon CT: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000; 95: 1113-1116
151. Johnson K, Choi Y, DeGroot E, et al: Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998; 160: 5130-5135
152. Stouthard JM, Levi M, Hack CE, et al: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76:738-742
153. Aupeix K, Hugel B, Martin T, et al: The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99:1546-1554
154. Soriano AO, Jy W, Chirinos JA, et al: Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005; 33:2540-2546
155. Fujimi S, Ogura H, Tanaka H, et al: Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. J Trauma 2002; 52: 443-448
156. Amaral A, Opal SM, Vincent JL: Coagulation in sepsis. Intensive Care Med 2004; 30: 1032-1040
157. Vervloet MG, Thijs LG, Hack CE: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44
158. Yan SB, Dhainut JF: Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29(Suppl):S69-S74
159. Xue M, Campbell D, Jackson CJ: Protein C is an autocrine growth factor for human skin keratinocytes, J Biol Chem 2007; 282: 13610-13616
160. Xue M, March L, Sambrook PN, et al: Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes. Ann Rheum Dis 2007; 66: 1574-1580
161. Regan LM, Steams-Kurosawa DJ, Kurosawa S, et al: The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem 1996; 271:17499-17503
162. Kurosawa S, Steams-Kurosawa DJ, Carson CW, et al: Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998; 91: 725-727
163. Yan SB, Helterbrand JD, Hartman DL, et al: Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001; 120:915-922
164. LaRosa SP, Opal SM, Utterback B, et al: Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10:25-31
165. Yan SB, Dhainaut JF: Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29(Suppl):S69-S74
166. Joyce DE, Gelbert L, Ciaccia A, et al: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 14:11199-111203
167. Jackson CJ, Xue M: Activated protein C-An anticoagulant that does more than stop clots. Int J Biochem Cell Biol 2008; 40: 2692-2697
168. Dutt T, Toh CH: The yin-yang of thrombin and activated protein C. Br J Haematology 2008; 140:505-515
169. Riewald M, Ruf W: Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 2005; 280:19808-19814
170. Bae JS, Yang L, Rezaie AR: Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104:2867-2872
171. Bae JS, Yang L, Manithody C, et al: The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110: 3909-3916
172. Shorr AF, Bernard GR, Dhainaut JF, et al: Protein C concentrations in severe sepsis: An early directional change in plasma levels predicts outcome. Crit Care 2006; 10:R92
173. Cinel I, Dellinger RP: Current treatment of severe sepsis. Curr Infect Dis Rep 2006; 8:358-365
174. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
175. Bae JS, Yang L, Manithody C, et al: Engineering a disulfide bond to stabilize the calcium binding loop of activated protein C eliminates its anticoagulant but not protective signaling properties. J Biol Chem 2007; 282:9251-9259
176. Kerschen EJ, Fernandez JA, Cooley BC, et al: Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204:2439-2448
177. Moake JL: Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600
178. Ruggeri ZM: Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1:1335-1342
179. Furlan M, Robles R, Galbusera M, et al: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New Engl J Med 1998; 339:1578-1584
180. Arya M, Anvari B, Romo GM, et al: Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: Studies using optical tweezers. Blood 2002; 99:3971-3977
181. Bianchi V, Robles R, Alberio L, et al: Von Willebrand factor-cleaving protease (AD-AMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100:710-713
182. Ono T, Mimuro J, Madoiwa S, et al: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006; 107:528-534
183. Nguyen TC, Liu A, Liu L, et al: Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92:121-124
184. Kremer Hovinga JA, Zeerleder S, Kessler P, et al: ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007; 5:2284-2290
185. Bockmeyer CL, Claus RA, Budde U, et al: Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93:137-140
186. Reiter RA, Varadi K, Turecek PL, et al: Changes in ADAMTS13 (von-Willebrand factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93:554-558
187. Martin K, Borgel D, Lerolle N, et al: Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35:2375-2382
188. Grewal PK, Uchiyama S, Ditto D, et al: The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008; 14:648-655
189. van't Veer C, van der Poll T. Keeping blood clots at bay in sepsis. Nat Med 2008; 14: 606-608
190. Treziack S, Cinel I, Dellinger RP, et al: Resuscitating the microcirculation in severe sepsis: The central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med 2008; 15:1-15